Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. Home

ESMO 2018 Congress: Highlights in Early Stage HER2+ Breast Cancer Prevention of Cardiotoxicity

Prof. Giuseppe Curigliano reports on key results on prevention of cardiotoxicity from ESMO 2018 Congress: 192PD: Randomized Trial of Lisinopril or Carvedilol for the Prevention of Cardiotoxicity in Patients with Early Stage HER2-Positive Breast Cancer Receiving Trastuzumab.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.